Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03521180 · ClinicalTrials.gov registry record
A Study to Evaluate Gluten Challenge on Immune Responses in Subjects With Celiac Disease
A clinical trial, sponsored by Celgene.
- Completed
- Registry status
- 5
- Enrollment target
NCT03521180: Completed study, sponsored by Celgene.
NCT03521180 is a clinical trial that has completed, run by Celgene. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03521180 has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- 5 participants
- Enrollment target
Study Summary
This is a model development, open label, no therapeutic treatment, three sequential group, short term-gluten challenge study in subjects with celiac disease. Immune responses are evaluated following gluten challenge. Approximately fifteen subjects with celiac disease will be enrolled in up to three sequential groups (5 subjects per group).
Primary Outcome
The number of gut-homing, activated, CD8+ αβ T cells and γδ T cells in PBMC will be reported separately by flow cytometry .
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-05-11 |
| Est. Completion | 2019-07-18 |
What the finished NCT03521180 record still lists
NCT03521180 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 5 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03521180 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03521180 about?
NCT03521180 is a clinical study titled "A Study to Evaluate Gluten Challenge on Immune Responses in Subjects With Celiac Disease". This is a model development, open label, no therapeutic treatment, three sequential group, short term-gluten challenge study in subjects with celiac disease. Immune responses are evaluated following gluten challenge. Approximately fifteen subjects with celiac disease will be enrolled in up to three...
What is the current status of trial NCT03521180?
This trial is currently completed. The enrollment target is 5 participants. The study started on 2018-05-11. Estimated completion is 2019-07-18.
Who is sponsoring clinical trial NCT03521180?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI